Liquid-based cytology

Computer-guided screening

Immu-no-chemistry

Find what you are looking for

Rely on the FDA-approved

**BD FocalPoint™ GS Imaging System**

for efficient and optimal interpretation of your slides
Rely on the FDA-approved BD FocalPoint™ GS Imaging System for assistance in your cervical cancer screening routine.

1. Reduced false negatives through the detection of significantly more dysplasia (1)

BD FocalPoint™ GS Imaging System shows superior dysplasia detection for BD SurePath™ Liquid-based cytology and conventional Pap smears as compared to the actual practice. (2-3-4-5-6-7). A FDA-approved clinical trial, comparing the BD FocalPoint™ GS Imaging System with manual screening of BD SurePath™ Pap test slides, found a:

- 24.5% increase in Cancer sensitivity
- 19.6% increase in HSIL +sensitivity
- 9.8% increase in LSIL+ sensitivity
- 9.2% increase in ASC-H+ sensitivity

2. Reduced unnecessary and inconvenient repeat testing by lowering your ASC-US result

3. Significantly increased productivity

- Only a limited number of fields of view,
- Up to 25% of the slides can be archived directly (optional)
- Up to 170 slides in an 8-hour work day
- Multiple possibilities to integrate LIS capabilities to accelerate data sharing
- Remote connectivity

References:
(1) Package insert of BD FocalPoint™ GS Imaging System. 

Product availability has to be confirmed by your local representative.